NexCAR19 for B-cell blood cancers that came back
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your cancer is a type of B-cell lymphoma or B-cell acute lymphoblastic leukemia that has come back or not responded to treatment.
- You are generally well enough for daily activities, with a performance status of 0 or 1.
- Your heart, kidney, and liver functions are adequate.
- You have not had certain other cancers, active infections, or serious heart problems recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of CAR T-cell therapy that targets two proteins on cancer cells (CD20 and CD19) for B-cell cancers like lymphoma and leukemia that have come back or not responded to other treatments. It might help you if your cancer hasn't been controlled by standard options.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Hear when a new Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.